Welcome to our dedicated page for Spruce Biosciences news (Ticker: SPRB), a resource for investors and traders seeking the latest updates and insights on Spruce Biosciences stock.
Spruce Biosciences, Inc. (SPRB) is a clinical-stage biopharmaceutical company pioneering non-steroidal therapies for rare endocrine disorders. This page serves as the definitive source for verified news and developments surrounding SPRB's innovative research and clinical programs.
Investors and medical professionals will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated content includes updates on SPRB's lead candidate tildacerfont for congenital adrenal hyperplasia (CAH), financial disclosures, and scientific conference presentations.
Key information categories include:
- Clinical trial phase updates
- Regulatory agency communications
- Peer-reviewed research publications
- Strategic industry collaborations
- Financial performance summaries
Bookmark this page for direct access to SPRB's official announcements, maintaining informed perspectives on therapeutic advancements in endocrine care.
Spruce Biosciences, Inc. (Nasdaq: SPRB) will participate in two upcoming investor conferences in May, featuring Fireside chats and 1x1 meetings. The events will include the JMP Securities Life Sciences Conference on May 13-14, 2024, and the RBC Capital Markets Global Healthcare Conference on May 14-15, 2024. The CEO, Javier Szwarcberg, M.D., M.P.H., will be presenting at these conferences, with webcasts available on the company's investor relations website.
Spruce Biosciences, Inc. announced additional poster presentations at the Pediatric Endocrine Society 2024 Annual Meeting, highlighting baseline characteristics of their CAHptain program for children with congenital adrenal hyperplasia (CAH) and the CAHmelia program for adults with CAH. The company is focused on developing therapies for rare endocrine disorders and will present abstracts at the conference in Chicago, IL.
FAQ
What is the current stock price of Spruce Biosciences (SPRB)?
What is the market cap of Spruce Biosciences (SPRB)?
